Omeros Corporation (OMER)
NASDAQ: OMER · Real-Time Price · USD
12.22
-1.06 (-7.98%)
May 15, 2026, 11:35 AM EDT - Market open
Omeros Revenue
Omeros had revenue of $9.89M in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $9.89M.
Revenue (ttm)
$9.89M
Revenue Growth
n/a
P/S Ratio
97.15
Revenue / Employee
$56,531
Employees
175
Market Cap
884.43M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 29.87M | -34.96M | -53.93% |
| Dec 31, 2017 | 64.83M | 23.21M | 55.77% |
| Dec 31, 2016 | 41.62M | 28.11M | 208.07% |
| Dec 31, 2015 | 13.51M | 12.97M | 2,406.31% |
| Dec 31, 2014 | 539.00K | -1.06M | -66.31% |
| Dec 31, 2013 | 1.60M | -4.42M | -73.43% |
| Dec 31, 2012 | 6.02M | 1.50M | 33.11% |
| Dec 31, 2011 | 4.52M | 2.42M | 114.92% |
| Dec 31, 2010 | 2.11M | 661.00K | 45.78% |
| Dec 31, 2009 | 1.44M | 274.00K | 23.42% |
| Dec 31, 2008 | 1.17M | -753.00K | -39.16% |
| Dec 31, 2007 | 1.92M | 1.52M | 380.75% |
| Dec 31, 2006 | 400.00K | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 369.49M |
| MannKind | 360.78M |
| Phathom Pharmaceuticals | 204.89M |
| Geron | 196.12M |
| MeiraGTx Holdings | 79.76M |
| Lexicon Pharmaceuticals | 69.64M |
OMER News
- 1 day ago - Omeros Earnings Call Transcript: Q1 2026 - Transcripts
- 1 day ago - Omeros reports Q1 adjusted EPS (24c), consensus (28c) - TheFly
- 1 day ago - Omeros Corporation Reports First Quarter 2026 Financial Results - Business Wire
- 1 day ago - Omeros options imply 10.8% move in share price post-earnings - TheFly
- 3 days ago - Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026 - Business Wire
- 11 days ago - Kyverna Therapeutics appoints Nadia Dac as chief commercial officer - TheFly
- 4 weeks ago - Omeros says CMS assigns permanent reimbursement J-code for YARTEMLEA - TheFly
- 4 weeks ago - CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug) - Business Wire